The Future of BioPharma blog provides timely coverage of news that directly impacts the business strategies of the biotech, pharmaceutical and medical device industries. In addition to news coverage, the Future of BioPharma blog features live event coverage from IIR's Biopharmaceutical and Healthcare division.
The current multiple sclerosis clinical trial at Cleveland Clinic, University Hospitals Seidman Cancer Center and Case Western Reserve University is working to treat and possible reverse the damage that patients suffering the disease are facing using the patient’s own Mesenchymal stem cells. The goal of the study is to examine if it is possible that stem cells can be a way to strengthen the immune system. his clinical study has already had two patients undergo the procedure and plan to have 24 patients enter the study over the next 2-3 years. According to Cleveland.com, there are clinical studies in Spain, Iran and China examining the same type of procedure.
The scientists collect the patients stem cells, then nurture them in a lab until they are grown and then inject them into the patients arm. The first patient saw his condition ease within a matter of weeks.
This video examines the study further:
This fall at theCell Therapy Commercialization Summit, there will be a full track examining clinical development strategies with speakers from Bioheart, Aldagen, Cytograft Tissue Engineering and more. For more information about the event,download the brochure.
Share this article with your social network, just click below to share now!
No comments :
Post a Comment